Ann Thorell
Directeur Financier/CFO chez SERES THERAPEUTICS, INC.
Fortune : 15 154 $ au 30/06/2024
Profil
Ann Marella Thorell is currently the Director at Living Beyond Breast Cancer.
She also holds current positions as an Independent Director at ESSA Pharma, Inc., a Director at ApcinteX Ltd., a Director at Carisma Therapeutics, Inc., and the Chief Financial & Accounting Officer at Seres Therapeutics, Inc. In her former roles, Ms. Thorell served as the Chairman at Vallon Pharmaceuticals, Inc. from 2022 to 2023.
She was also the COO, CFO, Secretary & Executive Director at Realm Therapeutics Plc from 2014 to 2019.
Additionally, she held positions as a Director at Capella Bioscience Ltd.
and Z Factor Ltd.
in 2021 and as the CFO, Treasurer, SVP & Chief Accounting Officer at Evelo Biosciences, Inc. in 2023.
Ms. Thorell also has experience as the President of Thorell Consulting and as the Chief Financial Officer at Palladio Biosciences, Inc. from 2019 to 2021.
She served as the Chief Accounting Officer at Centessa Pharmaceuticals Plc from 2021 to 2022.
Ms. Thorell obtained her undergraduate degree from Lehigh University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ESSA PHARMA INC
0,01% | 25/03/2024 | 2 881 ( 0,01% ) | 15 154 $ | 30/06/2024 |
EVELO BIOSCIENCES, INC.
0,12% | 27/11/2023 | 22 778 ( 0,12% ) | - $ | 30/06/2024 |
Postes actifs de Ann Thorell
| Sociétés | Poste | Début |
|---|---|---|
| ESSA PHARMA INC. | Directeur/Membre du Conseil | 31/07/2019 |
| SERES THERAPEUTICS, INC. | Directeur Financier/CFO | 25/03/2024 |
| CARISMA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 30/06/2024 |
ApcinteX Ltd.
 ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 29/01/2021 |
| Living Beyond Breast Cancer | Directeur/Membre du Conseil | - |
Anciens postes connus de Ann Thorell
| Sociétés | Poste | Fin |
|---|---|---|
| EVELO BIOSCIENCES, INC. | Directeur Financier/CFO | 20/11/2023 |
| GRI BIOPAR | Président | 21/04/2023 |
| CENTESSA PHARMACEUTICALS PLC | Comptroller/Controller/Auditor | 31/07/2022 |
Z Factor Ltd.
 Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Directeur/Membre du Conseil | 31/07/2022 |
| ░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Ann Thorell
| Lehigh University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| ESSA PHARMA INC. | Health Technology |
| SERES THERAPEUTICS, INC. | Health Technology |
| EVELO BIOSCIENCES, INC. | Health Technology |
| CENTESSA PHARMACEUTICALS PLC | Health Technology |
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Realm Therapeutics Plc
 Realm Therapeutics Plc Pharmaceuticals: MajorHealth Technology Realm Therapeutics Plc engages in the development of novel therapeutics. It focuses on the prescription treatments for immune mediated diseases in adults and children. The company was founded on April 21, 2006 and is headquartered in Malvern, PA. | Health Technology |
| Living Beyond Breast Cancer | |
Capella Bioscience Ltd.
 Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Z Factor Ltd.
Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Health Technology |
ApcinteX Ltd.
ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Health Technology |
Thorell Consulting
 Thorell Consulting Miscellaneous Commercial ServicesCommercial Services Thorell Consulting provides business consulting services. The private company is based in New York. | Commercial Services |
Palladio Biosciences, Inc.
 Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Health Technology |
Vallon Pharmaceuticals, Inc.
 Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA. | Health Technology |
